Rubella
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Rubella
- Therapeutic area
- Infectious Disease
- rubella
- Rubella infection
- Rubella virus caused disease or disorder
- Rubella virus disease or disorder
- Rubella virus infectious disease
- german measles
- three-Day Measles
- three day measles
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Mild
- MONDO ID
- MONDO:0004656
- Parent condition
- MONDO:0100329
Related records
Broader conditions (7)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (1)
- Congenital rubella syndrome
Trials (82)
- 300 Antibody Diagnostic Test Kit
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Co-administration Study of OCV, TCV and MR
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
- Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
- Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
- Immune Responses to Two Dose Varivax +/- MMR-II
Approved drugs (1)
- Rubella virus, live attenuated
Other linked drugs (2)
- Measles virus, live attenuated
- Mumps virus, live attenuated